MPLNET.com » Test Menu » Chronic Lymphocytic Leukemia (CLL) Panel by FISH Client Login | Email | Phone: 1.800.932.2943

Chronic Lymphocytic Leukemia (CLL) Panel by FISH

Test Code

F CLL

Test Synonyms

MYB (6q23), ATM (11q22.3), +12, DLEU1 (13q14.3), TP53 (17p13)

Associations

Chronic Lymphocytic Leukemia(CLL)

The Vysis CLL Fish probe kit is indicated for detecting deletion of the LSI TP53 probe target (17p-) as an aid in identifying those patients with CLL for whom treatment with VENCLEXTA® (venetoclax) is indicated. Vysis CLL FISH Probe Kit is not intended for monitoring of residual disease

Methodology

Fluorescence in situ Hybridization (FISH)

Turnaround Time

3-5 days

Specimen Requirements

5mL peripheral blood in sodium heparin
3mL bone marrow in sodium heparin
Fixed cytogenetically prepared cells in sterile centrifuge tube with pellet visible in 3:1, Methanol:Acetic Acid

Specimen Stability
Blood and bone marrow = 4°C to 25°C, specimens are stable up to 72 hours
Fixed cell pellets are stable for years when stored at -28°C to 15°C
Storage & Handling

4°C to 25°C during transit, but specimens may be transported on refrigerated gel packs. Do not allow the gel pack to come in contact with the specimen. Do not freeze. Extreme temperatures should be avoided.

Causes for Rejection

Clotted specimen; Specimens exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells

Reference Range

See report

Description

Leukemias are a diverse group of diseases often characterized by multiple genetic aberrations distributed across the genome. In some cases, the same genetic aberrations are shared by different types of leukemia. Fluorescence in situ hybridization (FISH) has improved the detection of genomic aberrations in chronic lymphocytic leukemia. Chromosomal aberrations are detected in approximately 82% of patients. The most frequent changes are deletion 13q (55%), deletion 11q (18%), trisomy 12 (16 %), deletion 17p (7%) and deletion 6q (6%). FISH can detect these abnormalities in either interphase or metaphase cells.

References
  1. Emili Montserrat. (2002). Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? The Hematology Journal. 3:7.
  2. Stilgenbauer S et al. (2002). Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 16(6):993-1007.
  3. Pettitt A.R. et al. (2001). Dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 98(3):814-822. 
  4. Dohner et al. (2000). Chromosomal Abnormalities in Chronic Lymphocytic Leukemia. NEJM. 343:1910.